PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



	al	ternational P	ional Patent Classification ⁶ :		(11) International Publication Number: WO 99/08673
A61K 31/275, C07C 255/61	2′	61K 31/275	31/275, C07C 255/61	A1	(43) International Publication Date: 25 February 1999 (25.02.99
(21) International Application Number: PCT/US (22) International Filing Date: 3 August 1998 ((30) Priority Data:	ta 68 64 ; I	ternational F ciority Data: 60/055,568 60/071,364 cplicant: [US/US]; P.0 ventor: ATW town, PA 18 gents: RODN	Data: 5,568 13 August 1997 (13.08.97) 1,364 15 January 1998 (15.01.98) At: BRISTOL-MYERS SQUIBB CO JS]; P.O. Box 4000, Princeton, NJ 08543-4 : ATWAL, Karnail, S.; 92 Valley View V PA 18940 (US). RODNEY, Burton et al.; Bristol-Myers Squippers 1998	7) U 8) U COMPAN 4000 (US) Way, Nev	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO paten (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian paten (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European paten (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.
(57) Abstract	na	bstract The (R)-enant		-trimethy	TRIMETHYLPROPYL) AMINO]METHYL]AMINO] BENZONITRIL propyl)amino]methyl]amino]benzonitrile as well as the correspondinale pattern baldness.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	$\mathbf{z}\mathbf{w}$	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ENANTIOMERS OF 4-[[(CYANOIMINO)[(1,2,2-TRIMETHYLPROPYL) AMINO METHYL AMINO BENZONITRILE

Field of the Invention

The present invention relates to the (R)-5 and (S)-enantiomers of 4-[[(cyanoimino)[(1,2,2trimethyl-propyl)amino]methyl]amino]benzonitrile, pharmaceutical compositions containing same, and a method for promoting hair growth employing such 10 enantiomers.

Backgound of the Invention

Potassium channel openers such as minoxidil (Upjohn), pinacidil (Lilly) and diazoxide (Shiseido 15 and Schering-Plough) are known for their hair growth stimulating activity. Thus, U.S. Patent Nos. 4,596,812 and 4,139,619 disclose use of minoxidil in the treatment of male pattern baldness, alopecia areata and balding in females. 20 U.S. Patent No. 4,057,636 discloses pinacidil. DE 3,827,467A discloses combinations of minoxidil and hydrocortisone or retinoids.

U.S. Patent No. 5,011,837 to Atwal et al discloses aryl cyanoguanidines which possess potassium channel activating activity and are useful therapy for hypertension and other cardiovascular disorders, for various central nervous system disorders, kidney and urinary problems as well as for the promotion of hair growth, for example in the treatment of male 30 pattern baldness (alopecia). These aryl cyanoguanidines have the structure

Ia
$$R^2$$
 $N-C=N$ $N-C=N$ $N+C-N+R_1$ R^4

and its possible tautomers

Ib
$$\begin{array}{c} R^2 \\ N = C - NH - R_1 \end{array}$$

and

5

Ic R^2 N-C=N N-C=N+F R^4

including pharmaceutically acceptable salts, wherein

 R_1 is alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, arylalkyl or cycloalkylalkyl;

O
$$(O)_m$$
 ... C —substituted amino, CF_3 or S^{-R_1} ;

R₃ and R₄ are each independently selected

form -R₂, hydrogen, alkyl, alkenyl, alkynyl,
haloalkyl, halo, alkoxy, -NHalkyl, -N-(alkyl)₂, -Salkyl, -O-aryl-alkyl, -S-arylalkyl or -S-aryl, -Oaryl, -NHaryl-alkyl, or R₂ and R₃ taken together
are a group which form a ring with the two carbon

atoms to which they are attached, which group is
selected from

m=1 or 2, n=3-5, p=2-4, X is 0, NR₅, CH₂; and R₅ is hydrogen or R₁.

Example 1 of U.S. Patent No. 5,011,837 discloses the preparation of 4-[[(cyanoimino)-[(1,2,2-trimethylpropyl)amino]benzonitrile

in the form of its racemic mixture.

5

10

15

20

25

PCT Application WO 92/02225 discloses a combination of a potassium channel opener and a 5- α -reductase inhibitor for promoting hair growth.

PCT Application WO 92/09259A discloses use of an androgen blocker and a potassium channel activator for stimulation of hair growth.

Description of the Invention

In accordance with the present invention, it has been unexpectedly found that the (R)-enantiomer of 4-[[(cyanoimino)[(1,2,2-trimethylpropyl)amino]-methyl]amino]benzonitrile, including pharmaceutically acceptable salts, thereof exhibits remarkable hair growth promoting activity which is superior in such regard to the corresponding (S)-enantiomer and the racemic mixture of such enantiomers. In fact, it has been found that the (R)-enantiomer is surprisingly and unexpectedly more effective in stimulating hair follicles to produce hair growth at a substantially faster rate as compared to the corresponding (S)-enantiomer.

The above (R)-enantiomer of the invention has the structure ${\tt I}$

The (R)-enantiomer I will be in substantially pure form, that is, will be at least 99% pure (R)-enantiomer and will at most contain 1% (S)-enantiomer.

In addition, in accordance with the present invention, it has been found that the (S)-enantiomer of 4-[[(cyanoimino)[(1,2,2-trimethyl-propyl)amino]methyl]amino]benzonitrile, including pharmaceutically acceptable salts thereof, exhibits excellent hair growth promoting activity.

The above (S)-enantiomer of the invention has the structure ${\tt II}$

II

5

10

15

20

25

30

The (S)-enantiomer II will be in substantially pure form, that is, will be at least 99% pure (S)-enantiomer and will at most contain 1% (R)-enantiomer.

The enantiomers of the invention form salts with a variety of inorganic and organic acids. The non-toxic pharmaceutically acceptable salts are preferred, although other salts may also be useful in isolating or purifying the product. Such pharmaceutically acceptable salts include those formed with hydrochloric acid, methanesulfonic acid, sulfuric acid, acetic acid, maleic acid, and the like. The salts are obtained by reacting the product with an equivalent amount of the acid in a medium in which the salt precipitates.

The present invention also includes pharmaceutical compositions containing the (R)-enantiomer of 4-[[(cyanoimino)[(1,2,2-trimethyl-propyl)amino]methyl]amino]benzonitrile or a

pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.

In addition, the present invention also includes pharmaceutical compositions containing the (S)-enantiomer of 4-[[(cyanoimino)[(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.

The (R)-enantiomer of the invention, that

10 is, (R)-4-[[(cyanoimino)[(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile may be prepared
according to the following reaction sequence:

Debenzylation

10%
Pd-C/
EtOH

3

Coupling Reaction

DMF-EtOH/
WSC

NC

NNaCN

NNaCN

H

NC N Me
N Me
N H
(R)-enantiomer

5

15

20

(prepared as described in Example 1 Part A of U.S. Patent No. 5,011,837)

The (S)-enantiomer of the invention, that is (S)-4-[[(cyanoimino)[(1,2,2-trimethylpropyl)-amino]methyl]amino]benzonitrile may be prepared according to the above reaction sequence for preparation of the (R)-enantiomer except that (S)-

 $\alpha\text{-methylbenzylamine}$ is employed in place of (R)- $\alpha\text{-}$ methylbenzylamine to eventually form

5 which is reacted with the 4-cyano-N'-(4-cyanophenyl)thiourea, monosodium salt to form the (S)-enantiomer (II).

The (R)-enantiomer I of the invention or the (S)-enantiomer II of the invention may be 10 formulation with other hair growth promoting compounds such as the potassium channel openers minoxidil (Upjohn) and/or diazoxide (Shiseido and Schering-Plough), as well as cromakalim and 15 pinacidil; a $5-\alpha$ -reductase inhibitor such as finasteride (Merck's Proscar®), terazosin HCl (Abbott's Hytrin®), or doxaosin mesylate (Pfizer's Cardura®); and/or an androgen blocker such as 4-(5-methoxyheptyl)-hexahydro-2(1H)-pentalenone as 20 disclosed in PCT Application WO 92/09259A, vasoconstrictors such as betamethasone dipropionate, corticosteroids such as hydrocortisone, and scopolamine, and cyproterone acetate.

25 The enantiomers of the invention may be administered via topical, oral, parenteral or rectal routes as described in U.S. Patent No. 5,011,837 (incorporated herein by reference), with topical being preferred. Thus, the enantiomers of the invention in suitable topical formulations are applied to the skin region where hair growth is desired.

Typical topical formulations for use herein will include conventional ointments, creams, lotions, waxes, gels, pastes, jellies, sprays, aerosols and the like in aqueous or non-aqueous

formulations. Examples of suitable topical formulations are disclosed in U.S. Patent Nos. 4,139,619 and 4,596,812 which are incorporated herein by reference.

The enantiomers of the invention will be used in an effective amount, that is, in an amount sufficient to promote hair growth or treat hair growth disorders, such that hair growth is increased or produced. A typical topical composition will include from about 0.01 to about 15% by weight, preferably from about 0.1 to about 10% by weight of the composition.

The topical formulations containing the enantiomers of the invention can be applied to the area to be treated such as the scalp in humans, by spraying, dabbing or swabbing to deliver the enantiomer to the region of the hair follicle. The formulations will be applied to the area of treatment on a routine basis prior to, during and subsequent to hair growth, at least once daily, and preferably two or more times daily.

15

20

25

The accompanying Figure is a graph showing the effect of a once daily application of each of the (R)- and (S)- enantiomers described herein on hair growth in male C3H mice.

The following Examples represent preferred embodiments of the present invention.

Example 1

30 (R)-4-[[(Cyanoimino)[(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile

A. (R)-1,2,2-Trimethylpropyl amine
$$\mathbf{M}\mathbf{H}_{\mathbf{H}}$$

The title compound was prepared according to the procedure described by Manley and Quast (*J. Med. Chem.* **1992**, *35*, 2327-2340) with some modification. A mixture of pinacolone (29 g, 290 mmol), (R)-α-methylbenzyl amine (17.6 g, 145 mmol) and p-toluenesulfonic acid monohydrate (300 mg) in toluene (150 mL) was refluxed using a Dean-Stark trap (to remove water from the reaction mixture) for 3 days. The solvent was evaporated and the residue was distilled at ca. 120-2°C (9 mm) to give 21 g (71% yield) of

15

20

25

30

as a colorless oil. This material was dissolved in anhydrous THF (210 mL) and treated at 0-2°C with borane-THF complex (1M, 206 mL, 206 mmol). The mixture was allowed to come to room temperature, stirred for 5h and concentrated in vacuo. To the resulting oily residue was carefully added ethanol (300 mL), and the mixture was refluxed for lh and concentrated again in vacuo. The residue was chromatographed over basic alumina (activity grade 1/hexane) giving colorless oil. Proton NMR and HPLC (YMC C18 S3 4.6X50 mm column/water-MeOH-H3PO4 90:10:0.2 to 10:90:0.2 gradient) indicated that this material was contaminated with ca. 10% of the (S,R)-diastereomer. Therefore, this mixture was resubjected to flash chromatography (silica gel/hexane-EtoAc-triethylamine 95:5:0.1) to afford

(11.45 g, 55.8 mmol, 54% yield). The above compound (11.45 g) and 10% palladium on carbon (1.5 g) were taken in EtOH (230 mL) and stirred under hydrogen for 12 hours. The mixture was filtered and the filtrate (ca. 230 mL) containing the title product was used as such for the next step as a ca. 0.24 M solution in ethanol (assumed 100% yield).

10 B. N-Cyano-N'-(4-cyanophenyl)thiourea, monosodium salt

The title compound was prepared according to 15 Example 1 Part A of U.S. Patent No. 5,011,837.

C. (R)-4-[[(Cyanoimino)[(1,2,2-trimethyl-propyl)amino]methyl]amino]benzonitrile

20

25

To a solution of Part B compound (6.0 g, 26.8 mmol) in DMF (150 mL) was sequentially added the solution of Part A compound (ca. 0.24 M in EtOH, 112 mL, 26.8 mmol) and 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (WSC) (6.0 g, 31.3 mmol). The mixture was stirred at room temperature for 3 hours, diluted with ethyl acetate and sequentially washed with 1N HCl, water and brine. The organic layer was dried over

magnesium sulfate, concentrated and the crude product was purified by flash chromatography on silica gel (hexanes-ethyl acetate-triethylamine 75:25:0.2) to afford a colorless foam. This

- material was recrystallized from isopropanol to give the title compound as a white solid (4.15 g, 57.6%), mp 159-60°C; $[\alpha]_D$ -180° C=1, MeOH; enantiomeric purity determined by chiral HPLC = 99% (ChiralPak AD column/hexane-isopropanol-
- 10 triethylamine 80:20:0.2); MS: 270 (M+H)+; 1 H NMR (CDCl₃) δ 8.65 (br s, lH), 7.69 (d, 2H, J=8.79 Hz), 7.37 (d, 2H, J=8.79 Hz), 4.93 (br d, lH), 3.83 (m, lH), 1.10 (d, lH, J=6.45 Hz), 0.90 (s, 9H).
- 15 Elemental analysis: calculated for $C_{15}H_{19}N_5$: C, 66.89; H, 7.11; N, 26.00 Found: C, 66.71; H, 7.14; N, 25.98.

Example 2

20 (S)-4-[[(Cyanoimino)[(1,2,2-trimethylpropyl)amino]-methyl]amino]benzonitrile

The title compound was prepared from Part B compound of Example 1 and (S)-1,2,2-trimethylpropyl amine (prepared according to Manley and Quast, J. Med. Chem., 1992, 35, 2327-2340) by the same procedure as described in Example 1, Part C. The product was obtained as a colorless solid, mp 158-59°C; [α]_D+189° C=1, MeOH; enantiomeric purity determined by chiral HPLC = 99.4% (ChiralPak AD column/hexane-isopropanol-triethylamine 80:20:0.2); MS: 270 (M+H)+; ¹H NMR (CDCl₃) δ 8.43 (br s, 1H), 7.69 (d, 2H, J=8.79 Hz), 7.37 (d, 2H, J=8.79 Hz),

4.93 (br d, 1H), 3.83 (m, 1H), 1.10 (d, 1H, J=6.45 Hz), 0.90 (s, 9H).

Example 3

5 Comparison of Example 1-(R)-Enantiomer and Example 2-(S)-Enantiomer Re Hair Growth in an Animal Model

The objective of the following described experiment was to compare and evaluate the <u>in vivo</u> effect of the Example 1-(R)-enantiomer and the Example 2-(S)-enantiomer on hair growth in an animal model. The two enantiomers were compared topically for hair growth in C3H mice.

15 Animal Model

10

20

25

30

35

The C3H mouse is a useful model for studying hair growth. Its usefulness rests with the fact that skin pigmentation of this animal is provided by the melanocytes of the hair follicle and not the epidermis. In the telogen or the resting phase of the hair follicle, the skin is pink. In the earliest phase of anagen or the growth phase, there is sudden graying of the skin and as the anagen phase progresses the skin becomes darker in color. In this study, visual observation was used as an in vivo assay of anagen induction. Furthermore as anagen develops, the skin thickness increases from a thin telogen skin to a measurably thickened anagen skin. Thus, recording the skin color and microscopic thickness of skin from these mice offers a sensitive, quantifiable and convenient method of assessing the phases of hair growth.

Groups of 20, six to seven week old male C3H mice with hair follicles in the resting phase of hair growth were used. At this stage in their life, the hair follicles remain in the telogen phase for up to 30 days or longer. This provides

an adequate window of time to screen drugs. Compounds that improve hair growth stimulate the hair follicles from the telogen to the anagen phase. This stimulation is manifested by the shortening of the telogen phase of the hair follicle cycle.

Animals were anesthetized with ketamine/ rompun (100 mg/Kg and 12 mg/Kg) IP and the hair over a defined dorsal area were closely clipped.

Animals with pink skin were treated topically 1x daily, 5 days per week with 50 microliters of a 2% solution of Example 1-(R)-enantiomer and a 2% solution of Example 1-(S)-enantiomer or vehicle by itself, applied to the dorsal area. The vehicle employed was ethanol/propylene glycol/water, 60/30/10. Treatment was continued for at least 4-5 weeks.

Animals were observed daily for side effects and changes to the test sites. All observations were documented. Test sites were graded weekly for changes in skin color and hair growth. In this study drug effects were evaluated using the visual observation of skin changing from pink to gray and resulting in hair growth.

25

30

35

10

15

20

Results

The percent of animals that induced hair follicle stimulation during the treatment period is illustrated in the accompanying Figure below. The most significant observation made between the two enantiomers is the difference in the time of onset of follicle stimulation. The time of onset for the Example 1-(R)-enantiomer was day 7 compared to day 11 for Example 2-(S)-enantiomer. The time of onset for the vehicle control was day 28. By day 11 of treatment the Example 1-(R)-enantiomer caused hair follicle stimulation in 40% of the test mice

compared to only 5% with Example 2-(S)-enantiomer.

By day 14, 50% of the animals treated with Example
1-(R)-enantiomer showed hair follicle stimulation
compared to 25% for Example 2-(S)-enantiomer. By

5 day 28, 85% of the animals treated with the Example
1-(R)-enantiomer showed hair follicle stimulation
as compared to 65% treated with Example 2-(S)enantiomer. Thus throughout the treatment period,
the group treated with Example 1-(R)-enantiomer

10 showed a higher incidence of hair follicle
stimulation as compared to the group treated with
Example 2-(S)-enantiomer.

The attached Figure shows the effect of lx daily topical application of Example l-(R)- enantiomer and Example 2-(S)-enantiomer.

15

20

25

30

In conclusion, these results in the C3H mice indicate that there is a remarkable difference between the Example 1-(R)-enantiomer and the Example 2-(S) enantiomer in their effect on hair follicle stimulation; in particular the (R)-enantiomer has a faster onset of action compared to the corresponding (S)-enantiomer.

These results are indeed surprising and unexpected especially in view of the vasorelaxant potencies of each of these enantiomers, which is generally recognized as an indication of hair growth promoting properties (Side Effects of Vasodilator Therapy, W.A. Pettinger et al, Hypertension, 1988, Vol. 11, II-34 to II-36, and Minoxidil Stimulates Cutaneous Blood Flow in Human Balding Scalps: Pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. R.C. Wester et al, J. Invest. Dermatol., 184, Vol. 82, 515-517).

Thus, while the IC_{50} for vasorelaxant potency of the (R)-enantiomer is 47 ± 17 nM versus 157 ± 35 nM for the (S)-enantiomer, as seen above, the hair growth promoting ability of the (R)- enantiomer for producing hair growth within 11 days of treatment is 8 times greater than the corresponding (S)-enantiomer.

What is Claimed is:

5

15

1. The (R)-enantiomer of 4-[[(cyanoimino)-[(1,2,2-trimethylpropyl)amino]methyl]amino]-benzonitrile or a pharmaceutically acceptable salt thereof.

- 2. The (R)-enantiomer as defined in Claim 1 substantially separated from its corresponding S-enantiomer.
- $$\rm 3. \>\>\>$ The (R)-enantiomer as defined in Claim 1 10 having the structure

in substantially pure form.

- 4. The (R)-enantiomer as defined in Claim 1 having an enantiomeric purity equal to at least 99%.
- 5. A pharmaceutical composition comprising the (R)-enantiomer as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.
- 6. A pharmaceutical combination which
 20 comprises the R-enantiomer as defined in Claim 1 in combination with another hair growth promoting agent.
- 7. A method for promoting hair growth which comprises administering to a human in need of treatment a therapeutically effective amount of the (R)-enantiomer of 4-[[(cyanoimino)[(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile or a pharmaceutically acceptable salt thereof.
- 8. The method as defined in Claim 7 wherein the (R)-enantiomer is administered systemically or topically.
 - 9. The method as defined in Claim 7 wherein the (R)-enantiomer is administered topically.

10. The method as defined in Claim 7 wherein the (R)-enantiomer is administered as a cream formulation, lotion formulation, liquid formulation or ointment formulation.

- 5 11. A method for treating male pattern baldness which comprises administering to a human in need of treatment a therapeutically effective amount of the R-enantiomer as defined in Claim 1.
- 12. The (S)-enantiomer of 4-[[(cyanoimino)10 [(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile or a pharmaceutically acceptable salt
 thereof.
 - 13. The (S)-enantiomer as defined in Claim
 12 substantially separated from its corresponding
 (R)-enantiomer.
 - 14. The (S)-enantiomer as defined in Claim 12 having the structure

in substantially pure form.

15

- 20 15. The (S)-enantiomer as defined in Claim 12 having an enantiomeric purity equal to at least 99%.
 - 16. A pharmaceutical composition comprising the (S)-enantiomer as defined in Claim 12 and a pharmaceutically acceptable carrier therefor.
 - 17. A pharmaceutical combination comprising the S-enantiomer as defined in Claim 12 in combination with another hair-growth promoting agent.
- 30 18. A method for promoting hair growth which comprises administering to a human in need of treatment a therapeutically effective amount of the (S)-enantiomer of 4-[[(cyanoimino)](1,2,2-

trimethylpropyl)amino]methyl]amino]benzonitrile or a pharmaceutically acceptable salt thereof.

19. The method as defined in Claim 18 wherein the (S)-enantiomer is administered systemically or topically.

- 20. The method as defined in Claim 18 wherein the (S)-enantiomer is administered topically.
- 21. The method as defined in Claim 18
 10 wherein the (S)-enantiomer is administered as a cream formulation, lotion formulation, liquid formulation or ointment formulation.
- 22. A method for treating male pattern baldness which comprises administering to a human in need of treatment a therapeutically effective amount of the (S)-enantiomer as defined in Claim 12.




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/16015

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 31/275; C07C 255/61 US CL :514/524; 558/419 According to International Patent Classification (IPC) or to both national classification and IPC						
	ocumentation searched (classification system followe	d by classification symbols)				
	514/524; 558/419	,				
Documentat	ion searched other than minimum documentation to the	e extent that such documents are included	in the fields searched			
None						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE						
C DOC	UMENTS CONCIDEDED TO BE DELEVANT					
C. DOC	UMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where ap	opropriate, of the relevant passages	Relevant to claim No.			
Y	US 5,011,837 A (ATWAL et al.) document.	30 April 1991, see entire	1-22			
Y	US 5,578,599 A (DIANI et al.) 26 November 1996, see entire document.					
Y	WO 92/09259 A1 (THE UPJOHN COMPANY) 11 June 1992, see 1-22 entire document.					
Furth	er documents are listed in the continuation of Box C	See patent family annex.				
• Sp	ecial categories of cited documents:	"T" later document published after the integrated date and not in conflict with the applications."				
	cument defining the general state of the art which is not considered be of particular relevance	the principle or theory underlying the	invention			
	lier document published on or after the international filing date cument which may throw doubts on priority claim(s) or which is	"X" document of particular relevance; the considered novel or cannot be conside when the document is taken alone				
cite	ed to establish the publication date of another citation or other ecial reason (as specified)	"Y" document of particular relevance; th				
	cument referring to an oral disclosure, use, exhibition or other ans	considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art				
	cument published prior to the international filing date but later than priority date claimed	*&" document member of the same patent family				
Date of the actual completion of the international search 26 SEPTEMBER 1998		Date of mailing of the international search report 22 OCT 1998				
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks		Authorized officer				
Box PCT Washington, D.C. 20231 PETER G. O'SULLIVAN						
	lo. (703) 305-3230	Telephone No. (703) 308-1235				